Analgesic Effect of Pregabalin in Patients Undergoing Total Abdominal Hysterectomy
Not Applicable
Withdrawn
- Conditions
- Pain
- Interventions
- Drug: Pregabalin administrationDrug: Placebo administration
- Registration Number
- NCT01466101
- Lead Sponsor
- Northwestern University
- Brief Summary
Pregabalin will decrease the total amount of opioid required in patients undergoing total abdominal hysterectomy. In addition, pregabalin will decrease the incidence of opioid-related side effects in patients undergoing total abdominal hysterectomy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
- ASA Physical Status 1-2
- Age 18-64
- BMI 18-35
- Scheduled for elective total abdominal hysterectomy (with or without bilateral salpingo-oophorectomy)
- Gender: Female
- Consent: Obtained
Read More
Exclusion Criteria
- Patient refusal
- Allergy to study medication(s)
- Preoperative use of gabapentinoids
- Preoperative use of anticonvulsants
- Daily use of analgesics
- Hepatic disease
- Renal insufficiency (Cr >2.0)
- Alcohol or drug abuse
- Pregnancy
- Language: Non-English speaking
- Patient expected to remain intubated after procedure
Dropout:
- Patient request
- Surgeon request
- Allergic reaction to pregabalin
- Surgical procedure significantly altered from scheduled procedure
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pregabalin administration Pregabalin administration Administration of pregabalin Placebo Placebo administration Administration of placebo
- Primary Outcome Measures
Name Time Method total hydromorphone consumption 24 hours total hydromorphone consumption 24 hours post operatively
- Secondary Outcome Measures
Name Time Method Pain Scores postoperative Post operative period Post operative pain scores